Imunexus Is Raising A$12M to Take IMX39 Into Humans

We discuss what investors are buying into, the path to first patient dosing in 2027 & the evidence behind its potential role in nerve repair...

related topics

Share To

Featured content

Related stories

SCROLL TO TOP